Advanced in Chronic Graft Versus Host Disease (cGvHD)

Hakan Ozdogu

Adana Dr. Turgut Noyan Application And Research Center, 
Adana, TR 
Advanced in Chronic Graft Versus Host Disease (cGvHD)
Adana Dr. Turgut Noyan Application And Research Center, 
Adana, TR 
OverviewLocationsClinical Research

Overview

Hakan Ozdogu practices in Adana, Turkey. Mr. Ozdogu is rated as an Advanced expert by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Anemia, Hemoglobinopathy, Sickle Cell Disease, Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 84 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Chronic Graft Versus Host Disease (cGvHD).

Gender
Male

Locations

Adana Dr. Turgut Noyan Application And Research Center, Adana, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
View 1 Less Clinical Trial

84 Total Publications

Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.
Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.
Journal: British journal of haematology
Published: March 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ozdogu's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile